Antimicrobial resistance is still often described as a clinical emergency, something confined to hospitals or specific therapeutic areas. And yet, this definition is no longer sufficient. What is emerging instead is a broader condition – less visible, but far more pervasive – in which resistance progressively reshapes the functioning of the entire healthcare system.
Italy makes this transition particularly evident. Here, antimicrobial resistance is not an emerging threat. It is already embedded in everyday clinical practice, influencing therapeutic choices, extending hospital stays and increasing the level of uncertainty clinicians must navigate. It is no longer an exception to manage, but a condition to operate within.
This is precisely what makes the Italian case so relevant. On the one hand, the country relies on a well-developed healthcare system, with strong clinical expertise and advanced care pathways. On the other, it continues to register some of the highest levels of antimicrobial resistance in Europe. Rather than a contradiction, this coexistence reveals how complex systems behave under pressure, where innovation and vulnerability can exist side by side.
Fragmentation and the limits of response
To understand the persistence of antimicrobial resistance in Italy, it is not enough to look at national strategies alone. Policies and surveillance systems are in place, yet their impact remains uneven.
Regional variability plays a decisive role. The adoption of antimicrobial stewardship programs, access to diagnostic tools and the implementation of infection prevention measures differ across territories. These differences are not merely operational gaps; they reflect the deeper structure of the healthcare system, where decentralization enables flexibility but also limits coherence.
The consequences extend beyond epidemiological indicators. Antimicrobial resistance alters the behavior of the system itself. Therapeutic options become less predictable, clinical decisions more complex, and even advanced medical procedures—those that depend on effective infection control—are indirectly affected. Resistance, in this sense, is not only a burden, but a constraint that reshapes what healthcare systems are able to do.
From emergency to governance
This is where the role of industry and governance becomes unavoidable. The development of new antibiotics, as well as alternative approaches, is widely recognized as essential, yet remains economically fragile. The incentives are misaligned: the need is high, but the return on investment uncertain.
At the same time, stewardship and prevention require coordination across actors who do not traditionally operate within a shared framework. The challenge is no longer purely scientific or clinical. It is systemic.
Italy has already taken steps through national action plans and strengthened surveillance networks. Awareness is growing, but the transition is still incomplete. What is needed now is a shift—from responding to emergencies to governing complexity.
Seen from this perspective, Italy is not simply a country facing a difficult situation. It is an early signal of a broader transition. A system in which antimicrobial resistance has already crossed a threshold, making visible the limits of existing models and the need for new ones.
Ultimately, antimicrobial resistance forces a more fundamental question: how can healthcare systems sustain innovation if the effectiveness of existing therapies continues to erode? It is a question that extends beyond microbiology into strategy and governance—and one that Italy is already confronting, anticipating a future that is likely to concern all advanced healthcare systems.
